AF-DX 116

(HB1501)

Product overview

  • Name
    AF-DX 116
  • Short description
    Selective, competitive M2 receptor antagonist
  • Biological description
    Selective and competitive M2 muscarinic receptor antagonist. Selective for M2 over M3 (Ki values are 64 and 786 nM respectively). Shows selectivity for cardiac muscarinic receptors. Shows hypertensive actions and increases heart rate in cold-stressed rats.
  • Alternative names
    Otenzepad
  • Biological action
    Antagonist
  • Purity
    >98%
  • Citations

Properties

  • Chemical name
    11-[[2-[(Diethylamino)methyl]-1-pip eridinyl]acetyl]-5,11-dihydro-6H-pyrido[2,3-b][1,4 ]benzodiazepin-6-one
  • Molecular Weight
    421.54
  • Chemical structure
    AF-DX 116  [102394-31-0]
  • Molecular Formula
    C24H31N5O2
  • CAS Number
    102394-31-0

Storing and Using Your Product

  • Storage instructions
    room temperature
  • Solubility overview
    soluble in DMSO (25mM, gentle warming)
  • Important
    This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use.

References for AF-DX 116

  • Binding profile of a novel cardioselective muscarine receptor antagonist, AF-DX 116, to membranes of peripheral tissues and brain in the rat.

    Hammer R et al (1986) Life Sci 38(18) : 1653-62.
    PubMedID: 3754610
  • Blood pressure and heart rate are increased by AF-DX 116, a selective M2 antagonist, in autonomic imbalanced and hypotensive rats caused by repeated cold stress.

    Hata T et al (2001) Jpn J Pharmacol 85(3) : 313-21.
    PubMedID: 11325025
  • BK channel β1 subunits regulate airway contraction secondary to M2 muscarinic acetylcholine receptor mediated depolarization.

    Semenov I et al (2011) J Physiol 589(Pt 7) : 1803-17.
    PubMedID: 21300746
The following papers have cited the use of AF-DX 116 (HB1501) from Hello Bio. If you have published a paper using this product, and it is not shown here, then please tell us! We will send you a free gift as a thank you!
  • Targeting muscarinic receptor subtypes as a therapeutic approach in dystonia and Parkinson’s disease

    Klisko DM(2017) Dissertation : 1:2627

Reviews & Product Guides